Table 3.

The Results of a Meta-Analysis of the Reduction in Skeletal-Related Events Using Bisphosphonate Therapy in Women with Breast Cancer

Bisphosphonate (Dose, Route of Administration)	Reduction in Risk of SRE	Relative Risk (95% CI)
Zoledronic acid, 4 mg IV	41%	0.59 (0.42–0.82)
Pamidronate, 90 mg IV	23%	0.77 (0.69–0.87)
Ibandronate, 6 mg IV	18%	0.82 (0.67–1.00)
Ibandronate, 50 mg PO	14%	0.86 (0.73–1.02)
Clodronate, 1600 mg PO	16%	0.84 (0.72–0.98)

Abbreviations: IV, intravenous; PO, by mouth; SRE, skeletal-related event.

Data from Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;CD003474.